Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17

被引:15
|
作者
Gargis, Amy S. [1 ]
Karlsson, Maria [1 ,2 ]
Paulick, Ashley L. [1 ]
Anderson, Karen F. [1 ]
Adamczyk, Michelle [1 ]
Vlachos, Nicholas [1 ]
Kent, Alyssa G. [1 ]
McAllister, Gillian A. [1 ]
McKay, Susannah L. [1 ]
Halpin, Alison L. [1 ]
Albrecht, Valerie [1 ]
Campbell, Davina [1 ]
Korhonen, Lauren [1 ]
Elkins, Christopher A. [1 ]
Rasheed, J. Kamile [1 ]
Guh, Alice Y. [1 ]
McDonald, L. Clifford [1 ]
Lutgring, Joseph D. [1 ]
机构
[1] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30329 USA
[2] Goldbelt C6 LLC, Chesapeake, VA USA
关键词
Clostridioides difficile; antibiotic resistance; vancomycin; metronidazole; agar dilution; ANTIMICROBIAL SUSCEPTIBILITY; RESISTANCE; INFECTION; CARE; EMERGENCE; EPIDEMIC;
D O I
10.1093/cid/ciac817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Reference susceptibility testing revealed that elevated minimum inhibitory concentrations (MICs) to vancomycin and metronidazole were rare among US Clostridioides difficile isolates. Ribotype 027 was associated with increased MICs to several antibiotics including fluoroquinolones and clindamycin. Background Antimicrobial susceptibility testing (AST) is not routinely performed for Clostridioides difficile and data evaluating minimum inhibitory concentrations (MICs) are limited. We performed AST and whole genome sequencing (WGS) for 593 C. difficile isolates collected between 2012 and 2017 through the Centers for Disease Control and Prevention's Emerging Infections Program. Methods MICs to 6 antimicrobial agents (ceftriaxone, clindamycin, meropenem, metronidazole, moxifloxacin, and vancomycin) were determined using the reference agar dilution method according to Clinical and Laboratory Standards Institute guidelines. Whole genome sequencing was performed on all isolates to detect the presence of genes or mutations previously associated with resistance. Results Among all isolates, 98.5% displayed a vancomycin MIC <= 2 mu g/mL and 97.3% displayed a metronidazole MIC <= 2 mu g/mL. Ribotype 027 (RT027) isolates displayed higher vancomycin MICs (MIC50: 2 mu g/mL; MIC90: 2 mu g/mL) than non-RT027 isolates (MIC50: 0.5 mu g/mL; MIC90: 1 mu g/mL) (P < .01). No vanA/B genes were detected. RT027 isolates also showed higher MICs to clindamycin and moxifloxacin and were more likely to harbor associated resistance genes or mutations. Conclusions Elevated MICs to antibiotics used for treatment of C. difficile infection were rare, and there was no increase in MICs over time. The lack of vanA/B genes or mutations consistently associated with elevated vancomycin MICs suggests there are multifactorial mechanisms of resistance. Ongoing surveillance of C. difficile using reference AST and WGS to monitor MIC trends and the presence of antibiotic resistance mechanisms is essential.
引用
收藏
页码:890 / 896
页数:7
相关论文
共 50 条
  • [21] Cryptosporidiosis Surveillance - United States, 2011-2012
    Painter, Julia E.
    Hlavsa, Michele C.
    Collier, Sarah A.
    Xiao, Lihua
    Yoder, Jonathan S.
    MMWR SURVEILLANCE SUMMARIES, 2015, 64 (03): : 1 - 13
  • [22] Assisted Reproductive Technology Surveillance - United States, 2012
    Sunderam, Saswati
    Kissin, Dmitry M.
    Crawford, Sara B.
    Folger, Suzanne G.
    Jamieson, Denise J.
    Warner, Lee
    Barfield, Wanda D.
    MMWR SURVEILLANCE SUMMARIES, 2015, 64 (06): : 1 - 29
  • [23] Giardiasis Surveillance - United States, 2011-2012
    Painter, Julia E.
    Gargano, Julia W.
    Collier, Sarah A.
    Yoder, Jonathan S.
    MMWR SURVEILLANCE SUMMARIES, 2015, 64 (03): : 15 - 25
  • [24] Trichinellosis Surveillance - United States, 2008-2012
    Wilson, Nana O.
    Hall, Rebecca L.
    Montgomery, Susan P.
    Jones, Jeffrey L.
    MMWR SURVEILLANCE SUMMARIES, 2015, 64 (01): : 1 - 8
  • [25] Evolution of anaerobe susceptibility testing in the United States
    Hecht, DW
    CLINICAL INFECTIOUS DISEASES, 2002, 35 : S28 - S35
  • [26] Complete genome sequences of Clostridioides difficile surveillance isolates representing the top 10 ribotypes from the Emerging Infections Program, United States, 2016
    Adamczyk, Michelle
    Vlachos, Nicholas
    Breaker, Erin
    Orazi, Giulia
    Paulick, Ashley L.
    Rowe, Lori A.
    Mcallister, Gillian
    Machado, Maria-Jose
    Korhonen, Lauren
    Guh, Alice Y.
    Rasheed, J. Kamile
    Karlsson, Maria
    Mckay, Susannah L.
    Lutgring, Joseph D.
    Gargis, Amy S.
    MICROBIOLOGY RESOURCE ANNOUNCEMENTS, 2024, 13 (07):
  • [27] A Comparative Analysis of Clostridioides difficile Infection Outcomes in Hospitalizations With and Without Colorectal Cancer in the United States
    Vikash, Fnu
    Vikash, Sindhu
    Kumar, Vikash
    Taj, Sobaan
    Pan, Chun-Wei
    Syed, Noor
    Katamreddy, Rewanth
    Hussain, Sana
    Dahiya, Dushyant Singh.
    Patel, Sunny
    Kotler, Donald P.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S177 - S178
  • [28] Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States
    Syeda Sahra
    Mohammad Abureesh
    Shivantha Amarnath
    Motasem Alkhayyat
    Rawan Badran
    Abdullah Jahangir
    Vivek Gumaste
    World Journal of Hepatology, 2021, 13 (08) : 926 - 938
  • [29] Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States
    Sahra, Syeda
    Abureesh, Mohammad
    Amarnath, Shivantha
    Alkhayyat, Motasem
    Badran, Rawan
    Jahangir, Abdullah
    Gumaste, Vivek
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (08) : 926 - 938
  • [30] Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
    Yiling Jiang
    Eric M. Sarpong
    Pamela Sears
    Engels N. Obi
    Infectious Diseases and Therapy, 2022, 11 : 111 - 126